The global dyspareunia market is expected to witness decent growth with the steady rise in the number of women suffering from the disease.
The global dyspareunia market is expected to witness decent growth with the steady rise in the number of women suffering from the disease.
Dyspareunia refers to the medical condition where pain occurs during or after sexual intercourse. Although men can also develop this condition but it is usually found in women. Women with dyspareunia may experience pain in the labia, clitoris or vagina.
There are several causes of dyspareunia, some of which are treatable and some are not. Common causes comprise an allergic reaction to clothing, douches or spermicides, vaginal dryness, urinary tract infections, side effects of drugs such as antihistamines and tamoxifen (Nolvadex and other brands), sexually transmitted diseases, vaginal yeast infections, and so on.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=70824
In its report on global dyspareunia market, Transparency Market Research offers a crystal clear view of the market. The study makes every attempt to cover all the critical growth strategies and market dynamics. It offers market insight and forecasts of the market and profiles leading companies that are operating in the global dyspareunia market.
Global Dyspareunia Market: Notable Developments
In terms of recent development, global dyspareunia market exhibits the following developments
AbbVie Inc., US-based biopharmaceutical company, reached an agreement to buy Allergan Plc for about 63 billion dollars in one of the biggest mergers of the healthcare industry. The two drug makers merge with the objective to create a combination that would deliver new sources of growth that they have grappled to find on their own. Big deals in the pharmaceutical sector normally indicate perennial challenges of competition, research and development, and growth.
Get COVID-19 Analysis on Dyspareunia Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=70824
In 2018, TherapeuticsMD announced it has received approval of Food and Drug Administration (FDA) for estradiol vaginal inserts (Imvexxy), which is designed for the treatment of moderate-to-severe dyspareunia. According to TherapeuticsMD, these inserts are the only products in their therapeutic class to offer 4 mcg and 10 mcg doses, the 4 mcg is the lowest available approved dose of vaginal estradiol. The estradiol vaginal inserts are used in the treatment of vaginal pain related to sexual activity, which is a symptom of vaginal atrophy (VVA) and vulvar, due to menopause.
TherapeuticsMD Inc, Allergan Plc., Laboratories Vivacy SAS, GTO Pharmaceutical LLC, Hormos Medical Oy, Danderyds Sjukhus AB, and EndoCeutics Inc are some of the renowned names that adorn the global dyspareunia market.
Global Dyspareunia Market: Key Trends
The global dyspareunia market is likely to be driven by the following factors:
Menopausal Women Suffering from Dyspareunias Drives Market Growth
Women with dyspareunia may experience superficial pain at the very entrance of the vagina, or deeper pain at the time of penetration or thrusting of the penis. Some women might also witness acute tightening of the vaginal muscles during penetration, a condition that is called vaginismus. Pain can range from severe to moderate. Reasons associated with dyspareunia could be physical or psychological, and they could also be related to menopause. Mostly menopausal women who suffer from dyspareunia drive the global dyspareunia market.
Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=70824
Global Dyspareunia Market: Geographical Analysis
In terms of region, the global dyspareunia market is divided into North America, Europe, Middle East and Africa, Asia Pacific, and Latin America. As per World Health Organization (WHO), the prevalence of dyspareunia in the United States is around 10% to 20%, with the leading causes varying by age group. Painful sex or dyspareunia reported by 7.5% of women in Britain. The disease is linked to poorer sexual, physical, relational and mental health.
Browse more Reports by Transparency Market Research:
Autotransfusion Devices Market: Increase in the number of cardiac patients across the globe has created a notable rise in the need for autotransfusion of patients, thereby driving the demand for autotransfusion devices. Thus, surge in the cardiac cases globally is projected to generate substantial sales opportunities in the global autotransfusion devices market in the upcoming years.
Hepatitis C Therapeutics Market: The market for Hepatitis C therapeutics remains in billions, with new combinations being patented every year, and each having their own market segment. They are at present one of the most sought after investment segment in the healthcare drugs industry.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453